Treatment of Acute Hypercapnic Respiratory Failure With OptiflowTM or Optiflow+DuetTM Nasal Cannula in COPD-patients

Launched by AALBORG UNIVERSITY HOSPITAL · Feb 13, 2024

Keywords

ClinConnect Summary

This clinical trial is examining how two different types of nasal cannulas—OptiflowTM and OptiflowTM+Duet—affect patients with Chronic Obstructive Pulmonary Disease (COPD) who are experiencing a serious breathing problem known as acute hypercapnic respiratory failure. The researchers believe that using these nasal cannulas with high-flow oxygen can help lower carbon dioxide levels in the blood and improve overall blood acidity, which is important for breathing and health. The trial aims to find out which nasal cannula is more effective in this situation and how well patients are able to stick to the treatment.

To participate in this study, individuals must be over 40 years old, have been diagnosed with COPD, and be experiencing a worsening of their condition that leads to high carbon dioxide levels in the blood. Notably, those who cannot tolerate non-invasive ventilation (a common breathing support method) will be included. Participants will receive high-flow oxygen through one of the nasal cannulas, and their breathing and blood levels will be monitored throughout the treatment. This trial is still in the planning stages, so no participants are currently being recruited. If you or someone you know is interested, it’s essential to talk with a healthcare provider for more information about eligibility and the potential benefits of joining this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age\> 40 years old.
• • A diagnosis of COPD, according to GOLD recommendations1, or clinical suspicion of COPD.
• • Patients admitted with exacerbation, according to GOLD recommendations1, causing acute hypercapnic respiratory failure (pH≤7.35, pCO2 \>6.0 kPa) who do not tolerate NIV treatment.
• Exclusion criteria:
• • Patients with acute hypercapnic respiratory failure caused by other diseases than COPD exacerbation, such as, but not limited to, acute heart failure, judged by the responsible clinician.
• • Patients with combined metabolic- and respiratory acidosis (HCO3 \< 21.8 mmol/l, (female), 22.5 mmol/l, (male), and/or lactate \>2.5 mmol/l).
• • Patients with terminal illness
• • Patients who are incapable of giving informed consent.